97832-05-8 Usage
Description
Bendamustine is an alkylating agent that is used in the synthesis of Bendamustine 3-Hydroxyprop-2-yl Ester (B132550), an impurity of the anticancer drug Bendamustine Hydrochloride (B132500). It is a nitrogen mustard derivative with a unique chemical structure that allows it to cross-link DNA strands, leading to cell cycle arrest and apoptosis in cancer cells.
Uses
Used in Pharmaceutical Industry:
Bendamustine is used as an intermediate in the synthesis of Bendamustine 3-Hydroxyprop-2-yl Ester (B132550), which is an impurity of the anticancer drug Bendamustine Hydrochloride (B132500). This impurity is important for the development and manufacturing of Bendamustine Hydrochloride, a medication used to treat various types of cancer, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Bendamustine is used as an anticancer agent for its ability to cross-link DNA strands, leading to cell cycle arrest and apoptosis in cancer cells. This makes it a valuable component in the development of cancer treatments, particularly for patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Enzyme inhibitor
This nitrogen mustard and anticancer drug (FWfree-acid = 358.26 g/mol; CAS
16506-27-7), also known by its code name SDX-105, its trade names
Treanda?, Treakisym?, Ribomustin?, and Levact?, as well as by its
systematic name 4-[5-[bis (2-chloroethyl) amino]-1-methylbenzimidazol-2-
yl]butanoic acid, is a relatively nonspecific DNA alkylating agent that
causes intra- and inter-strand cross-links. Bendamustine is used in the
treatment of chronic lymphocytic leukemia (CLL), Hodgkin’s disease, non-
Hodgkin’s lymphoma, multiple myeloma and lung cancer.
Pharmacokinetics: After intravenous infusion, >95% of the drug becomes
protein-bound, mainly to albumin; however, only free bendamustine is
active. Bendamustine is metabolized by liver cytochrome p450, and
elimination (renal) is biphasic, with an initial half-life of 6–10 minutes and a
terminal half-life of approximately 30 minutes.
Check Digit Verification of cas no
The CAS Registry Mumber 97832-05-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,8,3 and 2 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 97832-05:
(7*9)+(6*7)+(5*8)+(4*3)+(3*2)+(2*0)+(1*5)=168
168 % 10 = 8
So 97832-05-8 is a valid CAS Registry Number.
InChI:InChI=1/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H
97832-05-8Relevant articles and documents
Discovery of a novel, efficient, and scalable route to bendamustine hydrochloride: The API in Treanda
Chen, Jian,Przyuski, Katrin,Roemmele, Renee,Bakale, Roger P.
, p. 1063 - 1072 (2011)
Process Research and Development activities leading to a new and efficient route to bendamustine hydrochloride, 1, the active ingredient in Treanda, a treatment for blood cancers, are disclosed. Two key features of this new process include a one-pot hydrogenation/dehydration sequence to construct the benzimidazole moiety and a novel reductive alkylation using chloroacetic acid and borane to install the bischloroethyl side chain. The number of synthetic steps has been significantly reduced to five from the eight in the current commercial process. The overall yield has been improved from 12% to 45%. Additionally, this new route eliminates chloroform, ethylene oxide, and sodium sulfide. Scale-up of the new route has been successfully demonstrated to prepare kilogram quantities of bendamustine hydrochloride.
Purification method of bendamustine hydrochloride
-
Paragraph 0043-0046, (2020/11/23)
The invention relates to a purification method for bendamustine hydrochloride. The purification method comprises the following steps: (1) adding an aqueous hydrochloric acid solution to a crude bendamustine hydrochloride product, carrying out stirring for dissolving, and adding active carbon for decolorization; (2) adding an inorganic alkali solution into a solution obtained in the step (1) to adjust the pH value of the solution to 1 to 4, and then carrying out cooling, recrystallizing and filtering to obtain a filter cake; and (3) leaching the filter cake obtained in the step (2), and carrying out drying to obtain bendamustine hydrochloride. By adopting the purification method, high-purity bendamustine hydrochloride can be obtained from the crude bendamustine hydrochloride product at lowtemperature and normal temperature, new impurities are prevented from being generated at high temperature, product purity is 99.8% or above, and the content of each single impurity is lower than 0.10%; and the method has the advantages of simple process, short period, refining yield of 90% or above, good product quality, capacity of meeting preparation requirements and suitability for industrial production.
Novel Solid Forms Of Bendamustine Hydrochloride
-
Paragraph 0099; 0100; 0101; 0102, (2016/07/05)
Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.